Brief · Use case · Public Affairs
EU Pricing Overview.
LiveOverviewUnderstand a live pricing and reimbursement file in one EU market: what changed, who moved it, what it means for your position and what would reopen the read.
EU Pricing Overview is a ready-made use case for Public Affairs. It ships under the Overview template.
For public-affairs and market-access leads who need to understand a file before acting on it. You get the answer first, how sure we are and what is most likely wrong, the established facts with a certainty label, and the signposts to watch. Every claim is cited to the open record or marked as a gap.
Add it to your library to reuse from New → From template. Edit the saved copy in your library on the service form.
The decision
What changed on a live pricing and reimbursement file in one EU market for an oral specialty product class, who moved it, what does it mean for the client’s position, and what would reopen the read?
What the overview covers
A file moves when a body acts on it. The overview identifies each move, who made it, and what the open record does and does not show.
| Part of the picture | What the overview explains | Where it looks |
|---|---|---|
| What changed | The decision or step that moved the file, in plain words and with its date, so you can tell what is new from what was already known.2 | The open record of the ministry, the HTA body and the payer. Where a step is not published, the overview says so and does not invent it. |
| Who moved it | Whether the ministry, the HTA body, an industry association or a patient group drove the change, and what each wanted. | Published statements, consultations and decisions of each party. |
| What it means for the position | What follows for the client, labeled as interpretation and kept apart from the facts.1,2 | The facts above, and the national and EU time limits that bound the process. |
| What would reopen the read | The events that would change the picture, such as a new decision, a deadline or a change in the rules.2,3 | The EU transparency rules, the HTA regulation’s phase-in, and the national calendar. |
What the overview does
The clock is part of the story. EU law requires national authorities to decide on a price within 90 days of a complete application and on inclusion in health insurance within a further 90 days, or within 180 days when the two are handled together. The overview checks the file against those limits and against the national timeline, and marks any step it cannot place as a gap.1
The rules around the file may be changing. The EU health technology assessment regulation applies in stages: joint clinical assessments began on 12 January 2025 for new cancer medicines and advanced therapies, extend to orphan medicines from 13 January 2028 and to all medicines from 13 January 2030. The overview says whether the product class is in scope and when.2
Access is measured, and it varies. The EFPIA Patients W.A.I.T. Indicator measures the days between marketing authorization and availability to patients, which for most countries means listing for reimbursement, and shows large differences between countries. The overview uses it only as context, because its cohorts and country sets change between editions.4
What is not in the open record stays out. The overview does not infer unpublished committee minutes or negotiating positions. Where a fact lives in a document you do not have, it says what that document would show.
Recommended length
Standard
A file read needs the main point, what changed and what it means, with the signposts to watch. Standard carries that in about 1,100 words without a terms table.
You can pick another length on the form. The other two stay available.
Assumptions the overview checks
The overview says which assumptions its conclusions rest on and names the most fragile one in its first paragraph. Examples for this subject:
- The file’s timeline in the open record is complete.
- The body described as moving the file is the one that holds the decision.
- The product class is in the scope the overview gives it.
Standards, guidance and sources
EU rules on pricing and reimbursement
Pricing policy and access
The decision practice behind the memo itself is on the template page.
What gets flagged
Any step in the file that is not in the open record, any attribution of a position to a party without a published source, and the one development that would reopen the read.
What arrives
- Bottom line
- Why it matters now
- What we know
- How it works
- What it means
- Terms and actors
- What would change this
What it will not do
It explains and does not recommend. If you need a recommendation on what to do next, the Decision Memo is the template for it.
It does not report unpublished committee minutes or negotiating positions, and it does not name sources it cannot cite.
It does not recommend an action. An overview explains; it does not decide. When you have a choice to make, a Decision Memo is the template for it.
It is one specialist’s reading of public sources. Check any figure you will act on against its primary source.
It does not replace reading the regulation, the filing or the guideline it cites.
References
- [1] Council of the European Communities. Council Directive 89/105/EEC of 21 December 1988 relating to the transparency of measures regulating the prices of medicinal products for human use and their inclusion in the scope of national health insurance systems. Check the national rules that implement it.
- [2] European Parliament and Council. Regulation (EU) 2021/2282 on health technology assessment. Application dates for medicinal products: 12 January 2025, 13 January 2028 and 13 January 2030. The phase-in dates are as given in the European Commission’s factsheet and EUR-Lex summaries; the regulation’s text was not read in full for this page.
- [3] World Health Organization. WHO guideline on country pharmaceutical pricing policies, second edition. Announced 28 September 2020.
- [4] EFPIA. EFPIA Patients W.A.I.T. Indicator survey. Successive editions. An industry association’s survey. Time to availability is measured from marketing authorization; for most countries it is the date of listing for reimbursement, and the edition cited here is the 2024 report.
Links checked 9 October 2026
These are the sources the template drew on. None of their authors or issuers has reviewed it.
About the Brief service
A Brief is a written answer from one specialist, at the depth you asked for. It arrives with its sources, and it closes by saying plainly what would change the conclusion. Nothing is hidden behind a summary, and anything the expert could not source is marked as a gap rather than filled in.
To edit a saved template, open New → Brief → From template, or the library rail on the service form.